Skip to main content
American Journal of Cancer Research logoLink to American Journal of Cancer Research
. 2026 Jan 25;16(1):365–369. doi: 10.62347/BRVV2647

STAC3 as a poor prognostic biomarker in renal clear cell carcinoma: relationship with immune infiltration

Yingnan Zhang 1,*, Jingtao Li 1,*, Luwen Feng 1,*, Yue Cheng 1, Linlin Shi 1, Qian Yang 1, Zhaoyang Wang 1, Xuan Yi 1, Guocai Zhong 1, Xueying Sun 1, Zhifeng Cheng 1, Min Guo 1
PMCID: PMC12877366  PMID: 41657805

During an internal review conducted by the author team, we identified several issues related to figure labeling and assembly. In Figure 7, the vertical axis labeling in certain panels was found to be inaccurate, and a scale bar has been added for improved clarity. Additionally, certain panels in Figure 7E and 7I were misassembled during figure preparation. In Figure 8E, the labeling of STAC3 expression was corrected. Furthermore, the CD80 expression image for the “769-P conditioned medium-treated THP1” group was found to be duplicated during figure assembly. The study flowchart has been revised accordingly. These corrections pertain solely to figure presentation and labeling and do not affect the underlying data, results, or conclusions of the study. We sincerely apologize for any errors and any inconvenience caused. The corrected Figures 1, 7 and 8 are shown below.

Figure 7.

Figure 7

STAC3 modulates tumorigenic behaviors in KIRC cells. A, B: STAC3 knockdown in KIRC cells (769-P, Caki-1); C: Sh-STAC3 impairs KIRC cell proliferation over 24, 48, and 72 hours; D: Intracellular calcium ion concentration was down-regulated after Sh-STAC3; E, F: Sh-STAC3 inhibits KIRC cell migration at 24 and 48 hours; G, H: Sh-STAC3 inhibits KIRC cell invasiveness at 36 hours; I, J: Sh-STAC3 decreases KIRC cell proliferation. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.

Figure 8.

Figure 8

STAC3 expression in KIRC tissues correlates with macrophage infiltration and impacts prognosis. A, B: Higher expression of STAC3 in tumor tissues compared to adjacent non-tumor tissues; C: Patients with higher STAC3 expression exhibit worse prognosis in clinical samples; D, E: Differential expression of STAC3 in KIRC tissues affects the expression of CD68, CD80, and CD163; F, G: Expression of incoming and outgoing signaling pathways and intercellular signaling communication in different cells; H: Co-culture of tumor cells-CM with macrophages and expression of sh-STAC3-macrophage associated proteins (STAC3, CD68, CD80, CD163). *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.

Figure 1.

Figure 1

Flowchart of this study.


Articles from American Journal of Cancer Research are provided here courtesy of e-Century Publishing Corporation

RESOURCES